Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy

Aberrant activation and interactions of hedgehog (HH) and PI3K/AKT/mTOR signaling pathways are frequently associated with high-risk medulloblastoma (MB). Thus, combined targeting of the HH and PI3K/AKT/mTOR pathways could be a viable therapeutic strategy to treat high-risk patients. Therefore, we investigated the anti-MB efficacies of combined HH inhibitor Vismodegib and PI3K-mTOR dual-inhibitor BEZ235 together or combined individually with cisplatin against high-risk MB. Using non-MYC- and MYC-amplified cell lines, and a xenograft mouse model, the in vitro and in vivo efficacies of these therapies on cell growth/survival and associated molecular mechanism(s) were investigated. Results showed that combined treatment of Vismodegib and BEZ235 together, or with cisplatin, significantly decreased MB cell growth/survival in a dose-dependent-fashion. Corresponding changes in the expression of targeted molecules following therapy were observed. Results demonstrated that inhibitors not only suppressed MB cell growth/survival when combined, but also significantly enhanced cisplatin-mediated cytotoxicity. Of these combinations, BEZ235 exhibited a significantly greater efficacy in enhancing cisplatin-mediated MB cytotoxicity. Results also demonstrated that the MYC-amplified MB lines showed a higher sensitivity to combined therapies compared to non-MYC-amplified cell lines. Therefore, we tested the efficacy of combined approaches against MYC-amplified MB growing in NSG mice. In vivo results showed that combination of Vismodegib and BEZ235 or their combination with cisplatin, significantly delayed MB tumor growth and increased survival of xenografted mice by targeting HH and mTOR pathways. Thus, our studies lay a foundation for translating these combined therapeutic strategies to the clinical setting to determine their efficacies in high-risk MB patients.

[1]  B. Rood,et al.  A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors , 2016, International journal of molecular sciences.

[2]  A. Fields,et al.  Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells , 2015, Clinical Cancer Research.

[3]  G. Canettieri,et al.  Translating Hedgehog in Cancer: Controlling Protein Synthesis. , 2016, Trends in molecular medicine.

[4]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[5]  Massimiliano Valeriani,et al.  Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor , 2016, Pediatric blood & cancer.

[6]  Xian-Jin Xie,et al.  Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma , 2013, Clinical Cancer Research.

[7]  K. Shokat,et al.  Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer , 2015, Front. Oncol..

[8]  Jer-Yen Yang,et al.  Targeting the Hedgehog Pathway in Pediatric Medulloblastoma , 2015, Cancers.

[9]  Eric C. Holland,et al.  Mouse Models of Brain Tumors and Their Applications in Preclinical Trials , 2006, Clinical Cancer Research.

[10]  F. Peale,et al.  PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition. , 2013, Cancer research.

[11]  K. Kurian,et al.  Pediatric Medulloblastoma – Update on Molecular Classification Driving Targeted Therapies , 2014, Front. Oncol..

[12]  T. Januario,et al.  Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation , 2011, Clinical Cancer Research.

[13]  Jing Yuan,et al.  Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma , 2010, Science Translational Medicine.

[14]  Z. Modrušan,et al.  Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. , 2011, Cancer research.

[15]  T. Curran,et al.  The Hedgehog's tale: developing strategies for targeting cancer , 2011, Nature Reviews Cancer.

[16]  Kenneth K Wang,et al.  The crosstalk of mTOR/S6K1 and Hedgehog pathways. , 2012, Cancer cell.

[17]  A. Adjei,et al.  Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. , 2014, Cancer treatment reviews.

[18]  Florence I. Raynaud,et al.  Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease , 2015, Cancer cell.

[19]  L. Di Marcotullio,et al.  Targeting GLI factors to inhibit the Hedgehog pathway. , 2015, Trends in pharmacological sciences.

[20]  P. Febbo,et al.  An animal model of MYC-driven medulloblastoma. , 2012, Cancer cell.

[21]  J. Olson,et al.  HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. , 2016, Cancer cell.

[22]  Roland Eils,et al.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.

[23]  L. Mainwaring,et al.  Divergent functions for eIF4E and S6 kinase by sonic hedgehog mitogenic signaling in the developing cerebellum , 2011, Oncogene.

[24]  K. Watabe,et al.  Mechanisms regulating glioma invasion. , 2015, Cancer letters.

[25]  T. MacDonald,et al.  Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. , 2011, The Journal of clinical investigation.

[26]  A. Arcaro,et al.  Targeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma. , 2015, Current molecular medicine.

[27]  Xin Shi,et al.  Chemotherapy dose-intensity and survival for childhood medulloblastoma. , 2012, Anticancer research.

[28]  C. Rudin,et al.  Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma , 2009, Science.

[29]  S. Joshi,et al.  Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan , 2016, Oncotarget.

[30]  Giles W. Robinson,et al.  Medulloblastoma—translating discoveries from the bench to the bedside , 2014, Nature Reviews Clinical Oncology.

[31]  L. Di Marcotullio,et al.  Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy. , 2015, Biochimica et Biophysica Acta.

[32]  B. Su,et al.  Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells , 2014, Oncotarget.

[33]  Wei Li,et al.  RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. , 2015, Cancer research.

[34]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[35]  J. Vose,et al.  Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-κB and mTOR Dual-Targeting Approach , 2013, Molecular Cancer Therapeutics.

[36]  Xiao-Yan Xu,et al.  PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. , 2015, American journal of cancer research.

[37]  Jean Y. Tang,et al.  Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  T. MacDonald,et al.  The rationale for targeted therapies in medulloblastoma. , 2014, Neuro-oncology.

[39]  Michael C. Rusch,et al.  Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  You-hong Cui,et al.  Medulloblastoma stem cells: Promising targets in medulloblastoma therapy , 2016, Cancer science.

[41]  C. Hawkins,et al.  Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma , 2014, Pediatric blood & cancer.

[42]  B. Coyle,et al.  In vitro models of medulloblastoma: Choosing the right tool for the job. , 2016, Journal of biotechnology.

[43]  M. Roussel,et al.  Role of MYC in Medulloblastoma. , 2013, Cold Spring Harbor perspectives in medicine.

[44]  M. Roussel,et al.  A mouse model of the most aggressive subgroup of human medulloblastoma. , 2012, Cancer cell.

[45]  Matthew J. Betts,et al.  Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.

[46]  M. Kool,et al.  Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma , 2015, Acta neuropathologica communications.

[47]  G. Cenacchi,et al.  Medullospheres from DAOY, UW228 and ONS-76 Cells: Increased Stem Cell Population and Proteomic Modifications , 2013, PloS one.

[48]  L. Platanias,et al.  New insights into malignant cell survival mechanisms in medulloblastoma. , 2014, Cancer cell & microenvironment.